Evidence map›Paper›PMID 35185520›Full record

ArticleFrontiers in aging neuroscience2021

Predicted Cognitive Conversion in Guiding Early Decision-Tailoring on Patients With Cognitive Impairment.

Yu Zheng, Yin Liu, Jiawen Wu, Yi Xie, Siyu Yang, Wanting Li, Huaiqing Sun, Qing He, Ting Wu

Open access · goldAbstract read
In one paragraph

Article in Frontiers in aging neuroscience, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
0.1field-weighted citation impact, top 55% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it, 1 citations in OpenAlex.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Yu ZhengDepartment of Rehabilitation Medicine, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Yin LiuDivision of Brain Rehabilitation, Department of Neurology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Jiawen WuDivision of Brain Rehabilitation, Department of Neurology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Yi XieIntensive Care Unit, Wuxi No.2 People's Hospital, Wuxi, China.
Siyu YangDivision of Brain Rehabilitation, Department of Neurology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Wanting LiDivision of Brain Rehabilitation, Department of Neurology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Huaiqing SunDivision of Brain Rehabilitation, Department of Neurology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Qing HeDepartment of Neurology, Xuzhou First People's Hospital, Xuzhou, China.
Ting WuDivision of Brain Rehabilitation, Department of Neurology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Nanjing Medical University · CNJiangsu Province Hospital · CNChina University of Mining and Technology · CNWuxi No.2 People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCognitive decline is the most dominant and patient-oriented symptom during the development of Alzheimer's disease (AD) and mild cognitive impairment (MCI). This study was designed to test the feasibility of hybrid convolutional neural networks and long-short-term memory (CNN-LSTM) modeling driven early decision-tailoring with the predicted long-term cognitive conversion in AD and MCI.

methodsCharacteristics of patients with AD or MCI covering demographic features, clinical features, and time-dependent neuropsychological-related features were fused into the hybrid CNN-LSTM modeling to predict cognitive conversion based on a 4-point change in the AD assessment scale-cognition score. Treatment reassignment rates were estimated based on the actual and predicted cognitive conversion at 3 and 6 months according to the prespecified principle; that is if the ADAS-cog score of the patient declines less than 4 points or increases at either follow-up time point, the medical treatment recommended upon their diagnosis would be considered insufficient. Therefore, it is recommended to upgrade the medical treatment upon diagnosis. Actual and predicted treatment reassignment rates were compared in the general population and subpopulations categorized by age, gender, symptom severity, and the intervention subtypes.

resultsA total of 224 patients were included in the analysis. The hybrid CNN-LSTM model achieved the mean AUC of 0.735 (95% CI: 0.701-0.769) at 3 months and 0.853 (95% CI: 0.814-0.892) at 6 months in predicting cognitive conversion status. The AUC at 6 months was significantly impacted when data collected at 3 months were withdrawn. The predicted cognitive conversion suggested a revision of medical treatment in 46.43% (104/224) of patients at 3 months and 54.02% (121/224) at 6 months as compared with 62.05% (139/224) at 3 months (

conclusionUsing the synergistic advances of deep learning modeling and featured longitudinal information, our hypothesis was preliminarily verified with the comparable predictive performance in cognitive conversion. Results provided the possibility of reassigned recommended treatment for those who may suffer from cognitive decline in the future. Considering the limited diversity of treatment strategies applied in this study, the real-world medical situation should be further simulated.

Indexed as

Alzheimer’s diseaseAlzheimer’s disease assessment scalecognitive conversiondecision-tailoringdeep learningmedical treatment reassignmentmild cognitive impairment

Identifiers

PMID35185520
PMCPMC8847748
OpenAlexW4210813030

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.